Pharmaceutical composition for treating atrophic vaginitis

A technology of atrophic vaginitis and composition, applied in the directions of drug combination, sexual diseases, pharmaceutical formula, etc., can solve the problems of irritation of mucous membrane, aggravation of the disease, irrational use of estrogen, etc., to achieve the effect of promoting recovery and unique formula

Inactive Publication Date: 2015-03-11
刘晓晖
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the irrational use of estrogen can easily lead to endometrial cancer and breast cancer, so this treatment has been controversial
To inhibit bacterial growth, put antibiotic powder in the vagina, but long-term use will lead to local flora imbalance, causing greater trouble
[0004] There are many suppositories and external lotions for the treatment of vaginitis in traditional Chinese medicine, but most of them are aimed at women of childbearing age. The prescriptions often contain dehumidification drugs such as Sophora flavescens, Cnidium, Kochia, and Smilax, while atrophic vaginitis The cause of the disease is mainly caused by the thinning of the mucous membrane. External application of the above bitter cold and dampness medicine will irritate the mucous membrane even more and lead to aggravation of the condition.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1, the weight ratio of raw materials: 20g Pittogonia bark, 10g trigonaria, 6g bobbin, 10g Tianmu magnolia, 6g mulberry, 10g cat's claw, 10g burnt malt, 10g burnt Shenqu, 10g ephedra root, saponins Thorn 2g, peach gum 6g, cassia twig 20g.

[0031] The preparation method of Example 1 is: mix Pittogonia bark, triangle grass, bobbin, magnolia, mulberry, cat's claw, scorched malt, scorched Shenqu, ephedra root, saponin thorn, peach gum, cassia twig, add water and decoct Boil, take the filtrate after 30 minutes, add water to the medicinal dregs and continue to decoct for 20 minutes, then take the filtrate, and wash the filtrate twice, once a day.

Embodiment 2

[0032] Example 2, the weight ratio of raw materials: 10 parts of Pittogonia bark, 6 parts of trigonum, 3 parts of bobbin, 6 parts of Tianmulan, 3 parts of Sangjisheng, 6 parts of cat's claw grass, 6 parts of burnt malt, 6 parts of burnt Shenqu 6 parts of ephedra root, 1 part of saponins, 3 parts of peach gum, and 10 parts of cassia twig.

Embodiment 3

[0033] Example 3, the weight ratio of raw materials: 20 parts of Pittogonia bark, 10 parts of triangular grass, 6 parts of bobbin, 10 parts of Tianmu magnolia, 6 parts of Sangji, 10 parts of cat's claw grass, 10 parts of burnt malt, 10 parts of Jiao Shenqu 10 parts of ephedra root, 2 parts of saponins, 6 parts of peach gum, and 20 parts of cassia twig.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating atrophic vaginitis and a preparation method thereof, which aim at solving the problem of treating atrophic vaginitis. The pharmaceutical composition is characterized by being prepared from the following active ingredients: cortex erythrina, smallflower bracketplant herb, tetrapanaxpapyrifer, Tianmu mountain magnolia immature flower, herba taxilli, radix ranunculi ternate, coking malt, scorch-fried medicated leaven, radix ephedrae, spina gleditsiae, peach gum, and cassia twig. Proved by clinical experiments, the drug for treating atrophic vaginitis has the characteristics of good curative effect and higher safety, thus being worth of clinical application and popularization.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a pharmaceutical composition for treating atrophic vaginitis. Background technique [0002] Atrophic vaginitis is a kind of non-specific vaginitis, which is common in postmenopausal elderly women. Due to the decline of ovarian function, many levels of estrogen decrease, vaginal wall atrophy, mucosal thinning, glycogen content in epithelial cells decreases, vaginal Ph As the value rises, the local resistance decreases, and pathogenic bacteria are easy to invade and reproduce and cause inflammation. The main symptoms are increased vaginal discharge and genital itching and burning sensation. Examination showed that the vagina showed senile changes, epithelial atrophy, folds disappeared, and the epithelium became smooth and thin. The vaginal mucosa is congested, with small bleeding spots, and sometimes superficial ulcers. [0003] The principle of treatment is to increa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/8998A61P15/02
Inventor 刘晓晖
Owner 刘晓晖
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap